0001209191-19-007851.txt : 20190206
0001209191-19-007851.hdr.sgml : 20190206
20190206180423
ACCESSION NUMBER: 0001209191-19-007851
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190204
FILED AS OF DATE: 20190206
DATE AS OF CHANGE: 20190206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Grigoriadis Dimitri E.
CENTRAL INDEX KEY: 0001423838
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 19572960
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-04
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001423838
Grigoriadis Dimitri E.
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Research Officer
Common Stock
2019-02-04
4
S
0
1375
88.1211
D
117066
D
Common Stock
2019-02-05
4
S
0
669
88.1667
D
118322
D
Common Stock
2019-02-05
4
S
0
401
88.1667
D
119071
D
Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 4, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.72 to $88.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 669 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,256) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.34 to $88.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 401 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (749) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
/s/ Darin Lippoldt, Attorney-in-Fact
2019-02-06